Figure 7.

SRGN/YAP promotes chemoresistance in vivo and is correlated with poor outcomes in BC patients. (A) Growth and chemosensitivity were monitored in tumors derived from cells with combined SRGN knockdown and YAP overexpression. Tumor volumes were periodically measured for each mouse treated with 5-Fu alone or in combination with VP, tumor growth curves were plotted, and tumor wet weights were recorded. Student's t-test, mean ± s.d. (n=5/group), _**** p < 0.0001. (B) Relevant protein levels in BC tissues were examined using immunohistochemistry, and expression scores were calculated. Student's t-test, _*** p < 0.001, _**** p < 0.0001. (C and D) Kaplan-Meier plots by SRGN and YAP expression were generated for BC patient cohorts in the TCGA database. Log-rank p values are shown.